ADB-CHMINACA

From WikiMD's Wellnesspedia

ADB-CHMINACA is a synthetic cannabinoid that has been identified in herbal blends. It was first identified in 2014 in Japan. Its structure is related to that of other synthetic cannabinoids including AB-CHMINACA, but it is unique in that it contains a valine-amino acid ester moiety.

History[edit | edit source]

ADB-CHMINACA was first identified in 2014 in Japan. It was among the most common synthetic cannabinoids identified in drug seizures by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in 2015.

Pharmacology[edit | edit source]

Like other synthetic cannabinoids, ADB-CHMINACA acts as a potent agonist for the CB1 receptor and CB2 receptor. It has been found to have a binding affinity of 0.52nM at CB1 and 0.88nM at CB2.

Legal status[edit | edit source]

ADB-CHMINACA is a controlled substance in many countries, including the United States, where it is a Schedule I controlled substance. It is also controlled in the European Union, where it is listed as a new psychoactive substance.

See also[edit | edit source]


ADB-CHMINACA Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD